Octave Bioscience Accelerates Leadership in Precision Care for Neurodegenerative Diseases with Addition of World-Class Commercial Executives

Jeron Evans joins as Chief Revenue Officer and Debbie Ledet joins as Chief Access Officer

MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the appointment of two key executives, Jeron Evans as Chief Revenue Officer and Debbie Ledet as Chief Access Officer. In these roles, Jeron and Debbie will be instrumental as Octave accelerates its commercial growth, patient access strategy, and adoption of Octave’s Precision Care Solution that combines proteomic biomarkers, AI MRI imaging capabilities, and virtual care management for a comprehensive view of the patient.

These hires come at a time when Octave is experiencing significant momentum across its multi-sided business. Octave recently appointed CEO Doug Biehn, who brings over 20 years of healthcare experience building and scaling growth businesses. Additionally, Octave recently expanded its precision care platform beyond multiple sclerosis into Parkinson’s with a $10 million grant from The Michael J. Fox Foundation to work toward the discovery, development, and validation of a custom protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic.

“We are excited to welcome Jeron and Debbie to the Octave leadership team,” said Doug Biehn, CEO of Octave Bioscience, Inc. “Both bring deep subject matter expertise in accelerating market development, adoption and reimbursement. Their experience is a great complement to our world class team and will help us realize our mission of reaching as many patients as possible and strengthening our leadership in neurodegenerative precision care.”

Jeron Evans has more than three decades of experience in commercial leadership roles across biotech, pharmaceutical, and medical device industries. Prior to joining Octave, Jeron built and scaled world-class commercial teams resulting in new standards of care and three successful acquisitions. Jeron is recognized for his ability to align high-performance teams focused on a patient-first approach, and will apply this knowledge as the leader of Octave’s revenue generation efforts.

“I am thrilled to join Octave at such a pivotal time in its growth,” said Jeron Evans. “I’m energized to be part of a company that is dedicated to the needs of MS patients and their physicians. Providing objective information and insights that enable both parties to make informed decisions regarding a patient’s longitudinal clinical management is very rewarding. I look forward to working with the MS community to enable Octave’s Precision Care Solution to become an integral part of the care journey.”

Debbie Ledet, a seasoned market access leader with over 20 years’ experience in laboratory diagnostics and the health care AI industry, will be responsible for securing CPT codes, medical policy coverage, and reimbursement within governmental and commercial health plans. Prior to joining Octave, Debbie held executive leadership roles in various companies that have created new standards of care and patient outcomes across several medical fields.

“Joining Octave means getting the chance to make a real difference in the lives of patients with neurodegenerative diseases,” said Debbie Ledet. “My background in healthcare and diagnostics has shown me first-hand how delivering a groundbreaking Precision Care Solution like Octave’s can help improve patient outcomes and dramatically reduce healthcare costs.”

Octave’s Precision Care Solution is now in use in leading MS centers of excellence, including 10 of the top 20 MS COE in the US, academic centers, and high-volume independent clinics across the U.S. As the only MS patient management tool that collects, analyzes, generates and monitors data, Octave’s solution enables providers, payers, pharma, and patients to improve treatment options and reduce costs.

This leadership expansion comes at an important growth phase for the company, when Octave is demonstrating rapid provider adoption and repeat usage, deepening strategic partnerships with Pharma companies to accelerate drug development and market differentiation, as well as providing health plans a value-based solution to improve health outcomes and reduce costs.

About Octave® Bioscience, Inc.

Octave® Bioscience, Inc. is a leading precision care company delivering a new paradigm of care for multiple sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of precision measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis (MS). The Octave Solution consists of proteomics, including the Octave MSDA Test, the first and only multivariate blood test, that measures disease activity; AI MRI imaging capabilities; and a virtual care management tool that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies nationwide, solidifying its commitment to advancing precision medicine and transforming the landscape of neurodegenerative disease care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240328910207/en/